Loading clinical trials...
Loading clinical trials...
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Conditions
Interventions
Enzyme Inhibitor Therapy
Laboratory Biomarker Analysis
+2 more
Locations
1
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Start Date
October 3, 2017
Primary Completion Date
October 20, 2022
Completion Date
October 30, 2022
Last Updated
December 6, 2023
NCT07545603
NCT07137494
NCT05969860
NCT07218341
NCT06870760
NCT03618550
Lead Sponsor
Rutgers, The State University of New Jersey
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions